Bison Wealth LLC Sells 11,596 Shares of Merck & Co., Inc. (NYSE:MRK)

Bison Wealth LLC lessened its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 36.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 20,330 shares of the company's stock after selling 11,596 shares during the period. Bison Wealth LLC's holdings in Merck & Co., Inc. were worth $2,022,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Midwest Capital Advisors LLC bought a new position in Merck & Co., Inc. during the 4th quarter valued at approximately $26,000. Financial Life Planners bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $28,000. Halbert Hargrove Global Advisors LLC purchased a new stake in Merck & Co., Inc. in the fourth quarter worth $28,000. Finally, Promus Capital LLC bought a new stake in Merck & Co., Inc. in the fourth quarter valued at $30,000. Hedge funds and other institutional investors own 76.07% of the company's stock.

Analyst Ratings Changes

MRK has been the subject of several research analyst reports. BMO Capital Markets dropped their target price on shares of Merck & Co., Inc. from $105.00 to $96.00 and set a "market perform" rating for the company in a research report on Wednesday, February 5th. UBS Group lowered their price objective on shares of Merck & Co., Inc. from $125.00 to $120.00 and set a "buy" rating for the company in a report on Wednesday, January 8th. TD Securities downgraded Merck & Co., Inc. from a "buy" rating to a "hold" rating and reduced their target price for the stock from $121.00 to $100.00 in a report on Monday, February 10th. Cantor Fitzgerald assumed coverage on Merck & Co., Inc. in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $85.00 target price for the company. Finally, StockNews.com lowered Merck & Co., Inc. from a "strong-buy" rating to a "buy" rating in a research report on Friday, April 25th. Twelve research analysts have rated the stock with a hold rating, eight have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $111.13.

Merck & Co., Inc. Stock Up 1.8 %

Shares of Merck & Co., Inc. stock opened at $84.70 on Wednesday. Merck & Co., Inc. has a twelve month low of $75.93 and a twelve month high of $134.63. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79. The company's 50 day moving average is $86.94 and its 200 day moving average is $94.77. The company has a market cap of $213.59 billion, a price-to-earnings ratio of 12.59, a price-to-earnings-growth ratio of 0.77 and a beta of 0.40.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported $2.22 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.06. The firm had revenue of $15.53 billion for the quarter, compared to analysts' expectations of $15.59 billion. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The company's revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.07 EPS. Research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. declared that its board has authorized a share repurchase plan on Tuesday, January 28th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the company to buy up to 4.1% of its stock through open market purchases. Stock buyback plans are often an indication that the company's board believes its shares are undervalued.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, insider Cristal N. Downing sold 2,361 shares of the company's stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $88.76, for a total value of $209,562.36. Following the completion of the sale, the insider now owns 7,085 shares in the company, valued at $628,864.60. This represents a 24.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Inge G. Thulin acquired 2,833 shares of the firm's stock in a transaction dated Thursday, February 6th. The stock was bought at an average cost of $88.25 per share, for a total transaction of $250,012.25. Following the purchase, the director now directly owns 2,933 shares of the company's stock, valued at approximately $258,837.25. This trade represents a 2,833.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company's stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.